Fosamax and Osteonecrosis of the Jaw: Examining the Causal Link
Latest update (2026-05)
FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]
From General Health Science to Focused Pharmacovigilance
From its origins as a specialized repository for developmental medicine and environmental health, the archive has long served as a bridge between clinical observation and broader public health awareness. The foundational commitment to documenting the interplay between therapeutic interventions and unintended outcomes has provided a framework for examining emerging safety signals across diverse medical domains. This heritage of rigorous, context-sensitive analysis now proves particularly relevant as attention shifts toward pharmaceutical agents with prolonged biological activity and their potential for localized tissue effects. The transition from general health science documentation to focused pharmacovigilance reflects a natural evolution of the archive's core mission: to trace the pathways from exposure to outcome without premature mechanistic closure. Within this expanded scope, the inquiry into bisphosphonate therapy and its association with maxillofacial complications represents a logical extension of established analytical principles. The archive's methodological approach—prioritizing temporal relationships and dose-response patterns over speculative biology—provides a stable foundation for examining how sustained pharmacological exposure may alter normal physiological processes in susceptible populations. This pivot from broad health information to targeted risk assessment maintains the neutral, evidence-oriented stance that has defined the repository's contribution to medical discourse.
Bisphosphonate Therapy and Jaw Complications: An Evidence-Based Bridge
Building on this legacy of rigorous pharmacovigilance, we now turn to a specific and serious adverse event associated with bisphosphonate therapy: osteonecrosis of the jaw (ONJ). Fosamax (alendronate sodium) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The drug works by inhibiting bone resorption, thereby increasing bone mass and reducing fracture risk. However, a serious adverse effect associated with bisphosphonate use, including Fosamax, is osteonecrosis of the jaw (ONJ). Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the maxillofacial region, often presenting with pain, swelling, infection, and delayed healing after dental procedures. Clinical presentation can vary, but ONJ is generally associated with tooth extraction, local infection, or spontaneous occurrence (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The condition can lead to significant morbidity, including chronic pain, difficulty eating, and secondary infections.
Mechanistic Pathways and Risk Factors for Fosamax-Associated ONJ
The mechanistic pathways linking Fosamax to ONJ are not fully elucidated, but current understanding suggests that bisphosphonates suppress bone turnover by inhibiting osteoclast activity. This suppression can impair the jawbone's ability to remodel and repair microdamage, particularly in areas subjected to mechanical stress or dental procedures. The jawbone has unique structural and cellular characteristics that may make it more susceptible to bisphosphonate-related complications, as highlighted by multiscale characterization studies that aim to better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077). Additionally, bisphosphonates may have anti-angiogenic effects, reducing blood supply to the jawbone and contributing to tissue necrosis. Risk factors for developing ONJ while taking Fosamax include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, or ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with longer duration of bisphosphonate exposure. For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).
For affected patients, causation considerations are complex. While Fosamax is associated with ONJ, the condition can also occur spontaneously or due to other factors such as cancer, radiation therapy, or dental infections. The presence of known risk factors, such as invasive dental procedures or concomitant medications, may increase the likelihood that Fosamax contributed to the development of ONJ. The duration of bisphosphonate use is also a relevant factor, as longer exposure may increase risk. Patients who develop ONJ while on Fosamax should be evaluated by a dental professional with experience in managing the condition, and discontinuation of the drug may be considered based on individual risk-benefit assessment. In summary, Fosamax is a bisphosphonate that can cause osteonecrosis of the jaw, particularly in patients with additional risk factors such as invasive dental procedures or concomitant therapies. The prescribing information includes warnings about this risk, but the rarity of the event and variability in onset make it challenging to predict. Patients and healthcare providers should be aware of the signs and symptoms of ONJ and consider preventive dental care before initiating bisphosphonate therapy.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
What is Fosamax and how does it work?
Fosamax (alendronate sodium) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). It works by inhibiting bone resorption, thereby increasing bone mass and reducing fracture risk.
Does Fosamax cause osteonecrosis of the jaw?
Yes, Fosamax is associated with osteonecrosis of the jaw (ONJ), a condition characterized by exposed, non-healing bone in the maxillofacial region. The prescribing information includes warnings about this risk, and ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).
What are the risk factors for developing ONJ while taking Fosamax?
Risk factors include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, or ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).
What should I do if I develop symptoms of ONJ while taking Fosamax?
Patients who develop ONJ while on Fosamax should be evaluated by a dental professional with experience in managing the condition. Discontinuation of the drug may be considered based on individual risk-benefit assessment. Preventive dental care before initiating bisphosphonate therapy is recommended.
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.